Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters

Hepatology Research

Volumn 38, Issue 12, 2008, Pages 1194-1203

  Araujo, Natalia M ^a   Branco Vieira, Monique ^a   Silva, Anita C M ^b   Pilotto, José H ^b   Grinsztejn, Beatriz ^b   de Almeida, Adilson José ^c   Trepo, Christian ^d   Gomes, Selma A ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c HOSPITAL UNIVERSITÁRIO GAFFRÉE E GUINLE   (Brazil)

^d INSERM   (France)

Author keywords

Hepatitis B virus; Mutations; Occult infection; Surface antigen; Transfection

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; EFAVIRENZ; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; LAMIVUDINE; RITONAVIR; STAVUDINE; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSFECTION; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; MOLECULAR CLONING; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIREMIA; VIRUS LOAD; VIRUS VIRULENCE;

EID: 55449090988     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00392.x     Document Type: Article

References (54)

1. Zuckerman JN, Zuckerman AJ. Current topics in hepatitis B. J Infect 2000; 41: 130-6.
2. Coursaget P, Le Cann P, Leboulleux D, Diop MT, Bao O, Coll AM. Detection of hepatitis B virus DNA by polymerase chain reaction in HBsAg negative Senegalese patients suffering from cirrhosis or primary liver cancer. FEMS Microbiol Lett 1991; 67: 35-8.
3. Gomes SA, Yoshida CF, Niel C. Detection of hepatitis B virus DNA in hepatitis B surface antigen-negative serum by polymerase chain reaction: evaluation of different primer pairs and conditions. Acta Virol 1996; 40: 133-8.
4. Jeantet D, Chemin I, Mandrand B, Zoulim F, Trepo C, Kay A. Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology 2002; 35: 1215-24.
5. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-57.
6. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-86.
7. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-70.
8. Villa E, Grottola A, Buttafoco P et al. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B. Dig Dis Sci 1995; 40: 8-13.
9. Chemin I, Trepo C. Clinical impact of occult HBV infections. J Clin Virol 2005; 34: S15-21.
10. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: Full-length genome and analysis of mutant surface promoter. Gastroenterology 2004; 127: 1356-71.
11. Yamamoto K, Horikita M, Tsuda F et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994; 68: 2671-6.
12. Carman WF, Van Deursen FJ, Mimms LT et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology 1997; 26: 1658-66.
13. Jeantet D, Chemin I, Mandrand B et al. Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 2004; 73: 508-15.
14. Hofer M, Joller-Jemelka HI, Grob PJ, Lüthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998; 17: 6-13.
15. Núñez M, Ríos P, Pérez-Olmeda M, Soriano V. Lack of "occult" hepatitis B virus infection in HIV-infected patients. AIDS 2002; 16: 2099-101.
16. Santos EA, Yoshida CF, Rolla VC et al. Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2003; 22: 92-8.
17. Nebbia G, Garcia-Diaz A, Ayliffe U et al. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 2007; 79: 1464-71.
18. Filippini P, Coppola N, Pisapia R et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006; 20: 1253-60.
19. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36: 869-75.
20. Vento S, di Perri G, Luzzati R et al. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet 1989; 1: 332-3.
21. Hino K, Basuni AA, Ireland J et al. Reappearance of hepatitis B surface antigen in immunocompromised individuals: Reinfection or reactivation? Dig Dis Sci 2002; 47: 415-18.
22. Núñez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. Clin Infect Dis 2003; 37: 1678-85.
23. Thibault V, Benhamou Y, Seguret C et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999; 37: 3013-16.
24. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-7.
25. Lok AS, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145-53.
26. Niel C, Moraes MT, Gaspar AM, Yoshida CF, Gomes SA. Genetic diversity of hepatitis B virus strains isolated in Rio de Janeiro, Brazil. J Med Virol 1994; 44: 180-6.
27. Moraes MT, Niel C, Gomes SA. A polymerase chain reaction-based assay to identify genotype F of hepatitis B virus. Braz J Med Biol Res 1999; 32: 45-9.
28. Sucupira MV, Mello FC, Santos EA et al. Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations. Mem Inst Oswaldo Cruz 2006; 101: 655-60.
29. Twu SJ, Detels R, Nelson K et al. Relationship of hepatitis B virus infection to human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 299-304.
30. Treitinger A, Spada C, Silva EL et al. Prevalence of serologic markers of HBV and HCV infection in HIV-1 seropositive patients in Florianópolis, Brazil. Braz J Infect Dis 1999; 3: 1-5.
31. Souza MG, Passos AD, Machado AA, Figueiredo JF, Esmeraldino LE. HIV and hepatitis B virus co-infection: Prevalence and risk factors. Rev Soc Bras Med Trop 2004; 37: 391-5.
32. Pavan MH, Aoki FH, Monteiro DT, Goncales NS, Escanhoela CA, Goncales Junior FL. Viral hepatitis in patients infected with human immunodeficiency virus. Braz J Infect Dis 2003; 7: 253-61.
33. Monteiro MR, do Nascimento MM, Passos AD, Figueiredo JF. Soroepidemiological survey of hepatitis B virus among HIV/AIDS patients in Belem, Para, Brasil. Rev Soc Bras Med Trop 2004; 37 (Suppl 2): 27-32.
34. de Almeida Pereira RA, Mussi AD, de Azevedo e Silva VC, Souto FJ. Hepatitis B Virus infection in HIV-positive population in Brazil: results of a survey in the state of Mato Grosso and a comparative analysis with other regions of Brazil. BMC Infect Dis 2006; 6: 34.
35. Koblin BA, Taylor PE, Rubinstein P, Stevens CE. Effect of duration of hepatitis B virus infection on the association between human immunodeficiency virus type-1 and hepatitis B viral replication. Hepatology 1992; 15: 590-2.
36. Thio CL, Netski DM, Myung J, Seaberg EC, Thomas DL. Changes in hepatitis B virus DNA levels with acute HIV infection. Clin Infect Dis 2004; 38: 1024-9.
37. Mills CT, Lee E, Perrillo R. Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. Gastroenterology 1990; 99: 519-24.
38. Colin JF, Cazals-Hatem D, Loriot MA et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-10.
39. Araujo NM, Mello FC, Yoshida CF, Niel C, Gomes SA. High proportion of subgroup A' (genotype A) among Brazilian isolates of Hepatitis B virus. Arch Virol 2004; 149: 1383-95.
40. Mello FC, Souto FJ, Nabuco LC et al. Hepatitis B virus genotypes circulating in Brazil: Molecular characterization of genotype F isolates. BMC Microbiol 2007; 7: 103.
41. Koibuchi T, Hitani A, Nakamura T et al. Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan. J Med Virol 2001; 64: 435-40.
42. Quarleri J, Moretti F, Bouzas MB et al. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses 2007; 23: 525-31.
43. Altfeld M, Rockstroh JK, Addo M et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 29: 306-9.
44. Rodríguez-Iñigo E, BartoloméJ, Ortiz-Movilla N et al. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection. J Virol 2005; 79: 15578-81.
45. Märschenz S, Endres AS, Brinckmann A et al. Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis. Gastroenterology 2006; 131: 765-80.
46. Jenna S, Sureau C. Mutations in the carboxyl-terminal domain of the small hepatitis B virus envelope protein impair the assembly of hepatitis delta virus particles. J Virol 1999; 73: 3351-8.
47. Besisik F, Karaca C, Akyüz F et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003; 38: 506-10.
48. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol 2007; 79: 1650-4.
49. Melegari M, Scaglioni PP, Wands JR Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-33.
50. Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449-55.
51. Delaney WE 4th, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-41.
52. Locarnini SA Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance. Hepatology 1998; 27: 294-7.
53. Torresi J, Earnest-Silveira L, Deliyannis G et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293: 305-13.
54. Gutiérrez C, Devesa M, Loureiro CL, León G, Liprandi F, Pujol FH. Molecular and serological evaluation of surface antigen negative hepatitis B virus infection in blood donors from Venezuela. J Med Virol 2004; 73: 200-7.